Company Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer.
The company’s product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials.
It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024.
The company was founded in 2002 and is based in Beijing, China.
| Country | China |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 758 |
| CEO | Wang Xu |
Contact Details
Address: Building No. 2, 38 Yongda Road Beijing, 102629 China | |
| Phone | 86 10 8920 2086 |
| Website | ysbiopharm.com |
Stock Details
| Ticker Symbol | LSB |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | CNY |
| CIK Code | 0001946399 |
| ISIN Number | KYG9845F1090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wang Xu | Chief Executive Officer and Director |
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research |
| Dr. Hui Shao C.F.A., M.B.A., Ph.D. | President, Chief Business Officer and Vice Chairman |
| Rui Yu M.B.A., M.S. | Chief Financial Officer and Director |
| Zhiyuan Ran | Head of Medical and Marketing Department |
| Dr. Zenaida Reynoso Mojares M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2025 | SCHEDULE 13D/A | Filing |
| Jul 15, 2025 | 6-K | Report of foreign issuer |
| Jul 8, 2025 | 6-K | Report of foreign issuer |
| May 12, 2025 | 6-K | Report of foreign issuer |
| May 6, 2025 | 6-K | Report of foreign issuer |
| Mar 25, 2025 | 6-K | Report of foreign issuer |
| Mar 14, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Mar 12, 2025 | 6-K | Report of foreign issuer |
| Dec 19, 2024 | 6-K | Report of foreign issuer |
| Dec 12, 2024 | 6-K | Report of foreign issuer |